Anavex Life Sciences Corp. utilizes the genetic medication for treatment of severe and devastating neurological disorders. It is focused on the rare diseases with no therapy available and high-risk CNS (Central Nervous System) disease patients (Alzheimer’s disease and Parkinson’s disease). Anavex Life Sciences Corp is a biopharmaceutical company developing the therapeutics for the neuro-developmental and neurodegenerative diseases. It is even producing the medications for the rarest disease such as Rett syndrome.
The medicine named ANAVEX®2-73 completed clinical trials for Alzheimer’s disease. This medication has potential to reverse or halt the course of the disease. There have been several anti-depressants, neuro-protective, anti-amnesic and anticonvulsant properties. The same medication has been used for Parkinson’s disease trials. The headquarters of the company are in New York, the US and the company are traded on NASDAQ with the symbol as AVXL. The company was incorporated in January 2004 with the tag of a clinical biopharmaceutical company. The concept and researches used by the company are very promising for neurological segment patients. The researches and developments in the pipeline include the clinical drug candidates for pre-clinical study. The company didn’t generate its revenues until September 2016 and remained under the research and development stages. As of now, the company has attained excellent results with its medications:
The lead compound of the company is developed for the treatment of Parkinson’s disease and other CNS issues. The issues such as neuro-developmental issues, Parkinson’s disease, Rett syndrome and epilepsy are controlled by this compound.
The company is a Sigma-1 agonist. There are neuroprotective benefits revealed through the oxidative stress and endoplasmic reticulum. The medication prevented the expression of caspase-3 which is an enzyme responsible for programmed cell death.
This is a preclinical drug having the action mechanism bridging treatment of cognitive impairments with modification of diseases.
It is a mixture of sigma 1 and sigma 2 agonist designed for treating visceral pain and neuropathic pain.
This is used for treating prostate cancer. The product has low molecular weight and exhibits sigma 1 receptors at nano-molar levels to suppress tumor and eradicate the source behind it.
Anavex Life Sciences Corp. competes with the major groups in the pharmaceutical industry. The 52-week high/ low values are $ 5.74/ $ 1.86. The market capitalization of the company at present is $ 181.097M. Dr. Christopher U. Missling is the CEO, President, and Chairman of the company and is leading towards the most rewarding ways for the company to excel in the biopharmaceutical niche. There are best researchers and analysts associated with Anavex Life Sciences to get the best medicines for the required CNS diseases. It is expected that the company will grow in its stock position in the years to come and will produce some of the most required results in the medical industry.
The stock analysts are undertaking AVXL as a prospective stock for the best futuristic approach. The company will probably lead towards the successful modes in the years to come and with the growth in market cap, Anavex Life Sciences will become a pioneer in the pharmaceutical industry.